Q-omics provides the consensus-scored NDUFA10 profile across patient tissues and cancer cell-line models. NDUFA10 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, NDUFA10 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, NDUFA10 protein abundance shows 21,261 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUAD, THCA, and GBM as cancer lineages where NDUFA10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFA10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFA10 survival associations across molecular data types. NDUFA10 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFA10 RNA expression–survival associations across cancer types. High NDUFA10 expression shows unfavorable associations in LUAD, ACC, CHOL and UCEC, but favorable associations in KIRC and MESO. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for NDUFA10 RNA expression.
This table summarizes NDUFA10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NDUFA10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFA10 shows lower tumor expression in THCA, KIRC and KICH and higher tumor expression in LIHC, LUSC and LUAD. The THCA box plot shows higher NDUFA10 RNA expression in normal versus tumor tissue (log2 FC = −0.376, t-test p < 0.001).
This table shows molecular features associated with NDUFA10 in patient tissues and cancer cell lines. In patient samples, NDUFA10 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NDUFA10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and UPPER_AERODIGESTIVE_TRACT.
